Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag + Tacrolimus in Refractory/Relapsed Aplastic Anemia
NCT04403321Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2020
- Primary completion
- Jul 2022
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tacrolimus in aplastic anemia (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 6 months. Started Jul 2020; status: completed.
02
Drugs
tacrolimus
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT04403321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04403321.